Promoter Aayush Agrawal, acting as trustee for the Aayush Agrawal Trust, has reported the creation and release of share pledges concerning Ajanta Pharma Limited. A total of 7,87,933 shares were pledged primarily for securing additional loans. Concurrently, a significant portion of 8,32,178 shares was released following loan repayments and to reduce margin requirements. The disclosures detail multiple transactions spanning late February and early March 2026.
Disclosure of Promoter Encumbrance Activity
This disclosure, dated 6th March, 2026, confirms the recent activities related to the pledging and release of shares held by Promoter Aayush Agrawal, specifically through the Aayush Agrawal Trust, in Ajanta Pharma Limited. The reporting period detailed transactions involving creation and release of pledges on the promoter’s total holdings in the company.
Key Transaction Figures
The announcement highlights the following key movements in pledged shares:
- Shares Pledged (Creation): A total of 7,87,933 shares were created as pledge. The primary reason cited for this creation was to secure additional loan financing.
- Shares Released (Release): A total of 8,32,178 shares had their pledges released. This release was attributed to loan repayment activities and the necessity to reduce the margin against existing facilities.
Detailed Pledge Release Schedule
The report provides an itemized log of several pledge releases occurring between 24th February 2026 and 5th March 2026. Many of these releases, particularly those on 2nd March and 4th March, were executed to reduce the margin held by various financial entities.
Notable entities involved in the releases include Aditya Birla Capital Ltd, Deutsche Bank A.G, HSBC InvestDirect Finance Service (India) Pvt Ltd, and Jio Finance Ltd. A significant creation of pledge occurred on 4th March 2026 for 5,74,933 shares in favor of Bajaj Finance Ltd, categorized as an increase to the margin requirement.
Post-Event Holding Status
As of the reporting date, the Aayush Agrawal Trust maintained a holding of 1,41,12,924 shares in Ajanta Pharma, representing 11.30% of the total share capital. Prior to the reported events, the trust had 82,48,407 shares (6.60%) already encumbered. The final net encumbered position reflects the aggregation of these complex creation and release activities across various lenders.
Source: BSE
